Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
sector : Finance tags : Fda save search
FDA approves Ligand's molluscum contagiosum treatment – Pharmaceutical Technology
Published: 2024-01-08 (Crawled : 10:00) - spacfeed.com
CPT 4 | $95.15 -1.52% 69K
|
Finance
|
| O: -0.46%
H: 1.63%
C: 1.54%
molluscum fda treatment technology
FDA says not to use certain hip implants from Synovo – Mass Device
Published: 2024-01-03 (Crawled : 23:00) - spacfeed.com
AQU | $10.89 0.28% 61K
|
n/a
|
| O: -0.09%
H: 9.11%
C: -0.09%
CPT 4 | $95.15 -1.52% 69K
|
Finance
|
| O: -0.44%
H: 1.62%
C: 0.44%
ONB 4 | $15.455 -1.5% 160K
|
Finance
|
| O: 0.24%
H: 1.75%
C: 0.6%
SIF 4 | $3.09 1.98% 120
|
Electronic Technology
|
| O: 3.47%
H: 0.41%
C: -4.16%
fda device
Gamida Cell’s Allogeneic Cell Therapy Omisirge® (omidubicel-onlv) Receives FDA Approval
Published: 2023-04-17 (Crawled : 22:00) - biospace.com/
MC | $51.08 -1.26% 44K
|
Finance
|
| O: -0.1%
H: 2.0%
C: 0.07%
omisirge fda approval cell therapy
AUM Biosciences Receives FDA Orphan Drug Designation for AUM302 for the Treatment of NeuroblastomaAUM302 has potential to be the first multi-kinase inhibitor class of drug in Neuroblastoma
Published: 2022-11-30 (Crawled : 15:00) - biospace.com/
MCAC | $11.22 60
|
Finance
|
| O: 0.0%
H: 0.1%
C: 0.1%
aum302 treatment fda designation drug potential
Sheppard Mullin Expands Life Sciences Team With FDA Regulatory Group
Published: 2022-03-09 (Crawled : 21:00) - biospace.com/
XYF | $3.87 -2.76% 4.8K
|
Finance
|
| O: 3.91%
H: 1.88%
C: -2.4%
fda life science group
FDA's Dr. Peter Marks, The COVID-19 Research Database, and Rep. Patrick Kennedy Recognized with Innovations in Regulatory Science Awards
Published: 2021-09-28 (Crawled : 20:00) - prnewswire.com
ARE | $116.385 -2.34% 39K
|
Finance
|
| O: -0.17%
H: 1.21%
C: 0.82%
covid fda research
Lyndra Therapeutics Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA for Lyndra’s Weekly Risperidone (LYN-005) for the Treatment of Adults with Schizophrenia and Other Indications
Published: 2021-07-19 (Crawled : 13:00) - biospace.com/
AIG | $73.03 -0.03% 340K
|
Finance
|
| O: -5.62%
H: 0.62%
C: -1.25%
treatment fda phase 2 schizophrenia positive
FDA Grants Rafael Pharmaceuticals Orphan Drug Designation for CPI-613® (Devimistat) for Treatment of Biliary Cancer Company reaches important milestone to advance potential novel therapy for this subset of gastrointestinal cancers
Published: 2021-06-29 (Crawled : 17:00) - biospace.com/
RFL 4 | $1.785 -1.92% 4.2K
|
Finance
|
| O: 0.31%
H: 3.04%
C: -2.82%
treatment fda potential test therapy cancer gastrointestinal drug cpi-613 milestone designation
FDA Grants Rafael Pharmaceuticals Orphan Drug Designation for CPI-613® (Devimistat) for Treatment of Biliary Cancer
Published: 2021-06-29 (Crawled : 16:00) - globenewswire.com
RFL 4 | $1.785 -1.92% 4.2K
|
Finance
|
| O: 0.31%
H: 3.04%
C: -2.82%
treatment fda cancer drug cpi-613 granted grant designation
Multi-Site Contributor Headlands Research Congratulates Biogen on FDA Approval of Aducanumab for Alzheimer’s Disease
Published: 2021-06-16 (Crawled : 15:15) - biospace.com/
KKR | $94.62 -1.27% 310K
|
Finance
|
| O: 0.66%
H: 1.75%
C: 1.73%
disease alzheimer fda fda approval research approval alzheimer’s alzheimer's disease alzheimer's
Cerevel Therapeutics Announces Fast Track Designation Granted by the U.S. FDA to CVL-871 for the Treatment of Dementia-Related Apathy
Published: 2021-06-15 (Crawled : 12:00) - biospace.com/
CERE 4 | $41.76 0.14% 180K
|
Finance
|
| O: 1.18%
H: 0.85%
C: -2.77%
treatment fda dementia fast track fast track designation designation
Organogenesis ReNu® Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation For Osteoarthritis of the Knee
Published: 2021-01-11 (Crawled : 14:03) - globenewswire.com
ORGO | $2.85 3.26% 93K
|
Finance
|
| O: 2.22%
H: 0.13%
C: -2.94%
therapy fda osteoarthritis designation rmat
UPDATE - Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Acute Myeloid Leukemia (AML)
Published: 2020-12-15 (Crawled : 17:02) - globenewswire.com
RFL 4 | $1.785 -1.92% 4.2K
|
Finance
|
| O: 2.24%
H: 8.21%
C: -7.01%
fda leukemia treatment fast track fda fast track cpi-613 myeloid leukemia fast track designation designation acute myeloid leukemia aml
Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Acute Myeloid Leukemia (AML)
Published: 2020-12-15 (Crawled : 14:02) - globenewswire.com
RFL 4 | $1.785 -1.92% 4.2K
|
Finance
|
| O: 2.24%
H: 8.21%
C: -7.01%
fda leukemia treatment fast track fda fast track cpi-613 myeloid leukemia fast track designation designation acute myeloid leukemia aml
Gainers vs Losers
| 49% | 51% |
Top 10 Gainers
TPET | $0.503 117.66% 21M
|
n/a
JAGX | $0.23 93.6% 310M
|
Health Technology
WISA 4 | $3.22 84.0% 56M
|
Electronic Technology
SXTC | $2.56 82.86% 11M
|
Health Technology
PALI | $6.57 57.93% 19M
|
Manufacturing
BTTR | $7.61 49.22% 1.8M
|
Manufacturing
PRSO | $1.79 40.95% 38M
|
Manufacturing
DYNT | $0.5203 40.47% 17M
|
Health Technology
MCBC | $13.755 38.52% 620K
|
Finance
SNGX | $0.51 32.09% 6.3M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.